Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.
BRCA1/2 deficiency
Breast cancer
Homologous recombination (HR)
Real-time PCR
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
21
05
2024
accepted:
18
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
aheadofprint
Résumé
Homologous recombination (HR) is a crucial DNA-repair mechanism, and its disruption can lead to the accumulation of mutations that initiate and promote cancer formation. The key HR genes, BRCA1 and BRCA2, are particularly significant as their germline pathogenic variants are associated with a hereditary predisposition to breast and/or ovarian cancer. The study was performed on 45 FFPE breast cancer tissues obtained from 24 and 21 patients, with and without the germline BRCA1/2 mutation, respectively. The expression of 11 genes: BRCA1, BRCA2, ATM, BARD1, FANCA, FANCB, FANCI, RAD50, RAD51D, BRIP1, and CHEK2 was assessed using Custom RT2 PCR Array (Qiagen), and results were analysed using R. Cancer tissues from patients with BRCA1 or BRCA2 germline mutations displayed no significant differences in the expression of the selected HR genes compared to BRCA1 or BRCA2 wild-type cancer tissues. In BRCA1 In cancer tissues harbouring either BRCA1 or BRCA2 germline mutations, no significant differences in expression were observed at the mRNA level of any tested HR genes, except BRCA1. However, the significant differences observed in BRCA1 expression between germline BRCA1
Identifiants
pubmed: 39080120
doi: 10.1007/s10549-024-07441-4
pii: 10.1007/s10549-024-07441-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerstwo Zdrowia
ID : SUBK.A290.22.077, SUBZ.A290.23.067, and SUBZ.C280.24.063
Organisme : Ministerstwo Zdrowia
ID : SUBK.A290.22.077, SUBZ.A290.23.067, and SUBZ.C280.24.063
Organisme : Ministerstwo Zdrowia
ID : SUBK.A290.22.077, SUBZ.A290.23.067, and SUBZ.C280.24.063
Informations de copyright
© 2024. The Author(s).
Références
Nardin S, Mora E, Varughese FM et al (2020) Breast cancer survivorship, quality of life, and late toxicities. Front Oncol. https://doi.org/10.3389/fonc.2020.00864
doi: 10.3389/fonc.2020.00864
pubmed: 32612947
pmcid: 7308500
Wasserman, A., Wasserman, E., & Mak, R. (2022) Recent Advances In Breast Cancer Treatments. Journal of Student Research, 10(4). https://doi.org/10.47611/jsrhs.v10i4.2123
Miglietta F, Bottosso M, Griguolo G et al (2022) Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 7:100409
doi: 10.1016/j.esmoop.2022.100409
pubmed: 35227965
pmcid: 8886005
Yersal O, Barutca S (2014) Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol 5:412. https://doi.org/10.5306/WJCO.V5.I3.412
doi: 10.5306/WJCO.V5.I3.412
pubmed: 25114856
pmcid: 4127612
Carvalho FM (2023) Triple-negative breast cancer: from none to multiple therapeutic targets in two decades. Front Oncol. https://doi.org/10.3389/fonc.2023.1244781
doi: 10.3389/fonc.2023.1244781
pubmed: 38348123
pmcid: 10722195
Zhao Y, Xiong D, Yang B et al (2023) Application of multigene panel detection in breast cancer. J Pak Med Assoc 73:1862–1868
doi: 10.47391/JPMA.6830
pubmed: 37817699
Chatterjee N, Walker GC (2017) Mechanisms of DNA damage, repair and mutagenesis. Environ Mol Mutagen 58:235. https://doi.org/10.1002/EM.22087
doi: 10.1002/EM.22087
pubmed: 28485537
pmcid: 5474181
Wang R, Sun Y, Li C et al (2023) Targeting the DNA damage response for cancer therapy. Int J Mol Sci 24:15907
doi: 10.3390/ijms242115907
pubmed: 37958890
pmcid: 10648182
Huang R, Zhou PK (2021) DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. https://doi.org/10.1038/s41392-021-00648-7
doi: 10.1038/s41392-021-00648-7
pubmed: 34961761
pmcid: 8712507
Ensminger M, Iloff L, Ebel C et al (2014) DNA breaks and chromosomal aberrations arise when replication meets base excision repair. J Cell Biol 206:29. https://doi.org/10.1083/JCB.201312078
doi: 10.1083/JCB.201312078
pubmed: 24982429
pmcid: 4085701
Creeden JF, Nanavaty NS, Einloth KR et al (2021) Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer. https://doi.org/10.1186/S12885-021-08863-9
doi: 10.1186/S12885-021-08863-9
pubmed: 34711195
pmcid: 8555001
Doig KD, Fellowes AP, Fox SB (2023) Homologous recombination repair deficiency: an overview for pathologists. Mod Pathol 36:100049
doi: 10.1016/j.modpat.2022.100049
pubmed: 36788098
Wang Y, Ung MH, Cantor S, Cheng C (2017) Computational investigation of homologous recombination DNA repair deficiency in sporadic breast cancer. Sci Rep. https://doi.org/10.1038/s41598-017-16138-2
doi: 10.1038/s41598-017-16138-2
pubmed: 29273810
pmcid: 5741769
Yamamoto H, Hirasawa A (2021) Homologous recombination deficiencies and hereditary tumors. Int J Mol Sci 23:348. https://doi.org/10.3390/IJMS23010348
doi: 10.3390/IJMS23010348
pubmed: 35008774
pmcid: 8745585
Chopra N, Tovey H, Pearson A et al (2020) Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun. https://doi.org/10.1038/s41467-020-16142-7
doi: 10.1038/s41467-020-16142-7
pubmed: 33328478
pmcid: 7744542
Dilmac S, Ozpolat B (2023) Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches. Cancers (Basel) 15:3642
doi: 10.3390/cancers15143642
pubmed: 37509303
Royfman R, Whiteley E, Noe O et al (2021) BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer. Future Oncol 17:2817–2830. https://doi.org/10.2217/FON-2021-0072
doi: 10.2217/FON-2021-0072
pubmed: 34058833
Ladan MM, van Gent DC, Jager A (2021) Homologous recombination deficiency testing for BRCA-like tumors: the road to clinical validation. Cancers (Basel) 13:1–23. https://doi.org/10.3390/CANCERS13051004
doi: 10.3390/CANCERS13051004
Sato K, Koyasu M, Nomura S et al (2017) Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations. Cancer Sci 108:2287. https://doi.org/10.1111/CAS.13350
doi: 10.1111/CAS.13350
pubmed: 28796317
pmcid: 5666035
Jachimowicz RD, Goergens J, Reinhardt HC (2019) DNA double-strand break repair pathway choice - from basic biology to clinical exploitation. Cell Cycle 18:1423–1434
doi: 10.1080/15384101.2019.1618542
pubmed: 31116084
pmcid: 6592229
Moutafi M, Economopoulou P, Rimm D, Psyrri A (2021) PARP inhibitors in head and neck cancer: molecular mechanisms, preclinical and clinical data. Oral Oncol 117:105292
doi: 10.1016/j.oraloncology.2021.105292
pubmed: 33862558
Sim HW, Galanis E, Khasraw M (2022) PARP inhibitors in glioma: a review of therapeutic opportunities. Cancers (Basel) 14:1003
doi: 10.3390/cancers14041003
pubmed: 35205750
Zhu S, Zhao J, Nie L et al (2022) Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P). BMC Med. https://doi.org/10.1186/s12916-022-02430-0
doi: 10.1186/s12916-022-02430-0
pubmed: 36581917
pmcid: 9801594
Toh MR, Ngeow J (2021) Homologous recombination deficiency: cancer predispositions and treatment implications. Oncologist 26:e1526–e1537. https://doi.org/10.1002/onco.13829
doi: 10.1002/onco.13829
pubmed: 34021944
pmcid: 8417864
Singh DD, Parveen A, Yadav DK (2021) Role of parp in tnbc: Mechanism of inhibition, clinical applications, and resistance. Biomedicines. 9:1512
doi: 10.3390/biomedicines9111512
pubmed: 34829741
pmcid: 8614648
Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E (2020) PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 8:564601. https://doi.org/10.3389/fcell.2020.564601
Galland L, Roussot N, Desmoulins I et al (2023) Clinical utility of genomic tests evaluating homologous recombination repair deficiency (HRD) for treatment decisions in early and metastatic breast cancer. Cancers (Basel) 15:1299
doi: 10.3390/cancers15041299
pubmed: 36831640
Kekeeva T, Andreeva Y, Tanas A et al (2023) HRD testing of ovarian cancer in routine practice: what are we dealing with? Int J Mol Sci. https://doi.org/10.3390/ijms241310497
doi: 10.3390/ijms241310497
pubmed: 37445679
pmcid: 10342032
Wang Z, Zhang J, Zhang Y et al (2018) Expression and mutations of BRCA in breast cancer and ovarian cancer: evidence from bioinformatics analyses. Int J Mol Med 42:3542–3550. https://doi.org/10.3892/ijmm.2018.3870
doi: 10.3892/ijmm.2018.3870
pubmed: 30221688
Custódio N, Savisaar R, Carvalho C et al (2022) Expression profiling in ovarian cancer reveals coordinated regulation of BRCA1/2 and homologous recombination genes. Biomedicines. https://doi.org/10.3390/biomedicines10020199
doi: 10.3390/biomedicines10020199
pubmed: 35203410
pmcid: 8868827
Kessous R, Octeau D, Klein K et al (2018) Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecol Oncol 148:553–558. https://doi.org/10.1016/j.ygyno.2018.01.017
doi: 10.1016/j.ygyno.2018.01.017
pubmed: 29395310
Sun S, Jiang K, Zeng J (2022) Differential expression of DNA damage repair genes after chemoradiotherapy and inhibition rate in different bladder cancer cells. Transl Androl Urol 11:1336–1344. https://doi.org/10.21037/tau-22-543
doi: 10.21037/tau-22-543
pubmed: 36217404
pmcid: 9547156
Albarakati N, Al-Ghamdi H, Al-Sowayan B, Alshareeda A (2023) Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients. Sci Rep. https://doi.org/10.1038/s41598-023-38923-y
doi: 10.1038/s41598-023-38923-y
pubmed: 37474724
pmcid: 10359419
Kim HS, Hwang IG, Min HY et al (2019) Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer. Oncol Lett 17:4383–4392. https://doi.org/10.3892/ol.2019.10132
doi: 10.3892/ol.2019.10132
pubmed: 30988810
pmcid: 6447901